CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix CRMD has moved beyond a narrow launch story. DefenCath is now the core commercial engine, while the Melinta acquisition added a broader anti-infective platform and a longer-term Rezzayo opportunity. The investment debate is no longer just about launch uptake. Investors are watching utilization, reimbursement, portfolio …